Related Experiment Video

Updated: Jun 3, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Newer antifungal agents

Ozden Türel1

  • 1Pediatric Infectious Diseases Department, Bakirkoy Maternity and Children's Research Hospital, Istanbul, Turkey.

Expert Review of Anti-Infective Therapy
|March 23, 2011
PubMed

Insights

New antifungal drugs like isavuconazole and ravuconazole show promise in combating rising fungal infections, particularly in immunocompromised patients. These agents offer broader effectiveness and improved tolerance, addressing critical needs in antifungal therapy.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Fungal infections are increasing due to a rise in immunocompromised individuals.
  • Antifungal resistance is a growing concern, necessitating novel therapeutic agents.
  • Existing treatments face challenges with resistance, toxicity, and bioavailability.

Purpose of the Study:

  • To review investigational antifungal agents including isavuconazole, ravuconazole, albaconazole, and aminocandin.
  • To highlight the development of new antifungal drugs with improved characteristics.
  • To address the need for agents with expanded effectiveness and reduced toxicity.

Main Methods:

  • Literature review of studies on new antifungal agents.
  • Focus on isavuconazole, ravuconazole, albaconazole, and aminocandin.
  • Analysis of available data from clinical trials, animal studies, and meeting abstracts.

Main Results:

  • Investigational agents like isavuconazole and ravuconazole demonstrate broad-spectrum activity, including against resistant pathogens.
  • These new drugs offer potential advantages such as extended half-lives, reduced drug interactions, and good tolerance.
  • Current data is largely from early-phase human studies, animal models, or abstracts.

Conclusions:

  • New antifungal agents show promise for treating challenging fungal infections.
  • Further randomized clinical trials are essential to fully establish the efficacy and safety of these drugs.
  • These investigational antifungals may offer solutions for resistant and emerging fungal pathogens.

More Related Videos

Quantifying the Antifungal Activity of Peptides Against Candida albicans06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...